{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T20:21:04Z","timestamp":1720729264884},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.coviro.2019.05.011","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:19:21Z","timestamp":1559096361000},"page":"iii-v","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Editorial overview: Antiviral strategies: Antiviral drug development for single-stranded RNA viruses"],"prefix":"10.1016","volume":"35","author":[{"given":"Margo A","family":"Brinton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard K","family":"Plemper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2019.05.011_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coviro.2019.04.002","article-title":"Nucleoside analogues for the treatment of coronavirus infections","volume":"35","author":"Pruijssers","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2019.05.011_bib0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coviro.2019.02.008","article-title":"Taming a beast: lessons from the domestication of hepatitis C virus","volume":"35","author":"Luna","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2019.05.011_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.coviro.2019.01.005","article-title":"Strategies for Zika drug discovery","volume":"35","author":"Zou","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2019.05.011_bib0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","article-title":"Baloxavir marboxil: the new influenza drug on the market","volume":"35","author":"O\u2019Hanlon","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2019.05.011_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.coviro.2019.02.009","article-title":"The intersection of sex and gender in the treatment of influenza","volume":"35","author":"Morgan","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2019.05.011_bib0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coviro.2019.03.001","article-title":"Current status of small molecule drug development for Ebola virus and other filoviruses","volume":"35","author":"Edwards","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2019.05.011_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2018.12.009","article-title":"Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses","volume":"35","author":"Du Pont","year":"2019","journal-title":"Curr Opin Virol"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T17:09:27Z","timestamp":1559754567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625719300513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":7,"alternative-id":["S1879625719300513"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2019.05.011","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Editorial overview: Antiviral strategies: Antiviral drug development for single-stranded RNA viruses","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2019.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}